Press releases
Find out more about Ferring latest announcements.
Press releases
-
Ferring Announces Positive Topline Phase 3 Results for SI-6603, an Investigational Treatment for Lumbar Disc Herniation
-The primary endpoint was met: SI-6603 showed statistically significant improvement in worst leg pain score versus control at 13 weeks after injection. SI-6603 was generally well-tolerated. Ferring’s clinical development partner, Seikagaku Corporation, plans to proceed with preparation for a Biologics License Application to the U.S. Food and Drug Administration. Parsippany, NJ – May 26, 2023 – Ferring Pharmaceuticals (Ferring) […]
-
Four Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, Presented at DDW 2023
-Data presentations highlight Ferring’s microbiome leadership and commitment to ongoing research Analyses review safety and efficacy data across various patient populations with co-morbidities and when treatment is administered by colonoscopy Additional analysis evaluates shifts in microbiome composition and clonal engraftment Saint-Prex, Switzerland and Parsippany, NJ, USA – 8 May, 2023 – Ferring Pharmaceuticals today announced three oral presentations and […]
-
Retrospective Analysis of Data Evaluating Safety and Efficacy of REBYOTA™ (fecal microbiota, live – jslm) in a Real-World Patient Population with Comorbidities and Risk Factors Published in Open Forum Infectious Diseases
-REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection Analysis is the first to evaluate safety and efficacy of REBYOTA in a real-world population with comorbidities and risk factors with up to six months of follow up Parsippany, […]